IRVINE, Calif., June 7 /PRNewswire/ -- Ophthalmic device manufacturer Refractec, Inc. today announced the promotion of Thomas G. Frinzi to the position of chief executive officer. Frinzi replaces Mitch Campbell who has left the company to pursue other entrepreneurial ventures.
For more than six years, Frinzi has held progressive executive positions at Refractec. As chief operating officer, he was responsible for the day-to-day management of the company and the global market growth for its core technology, NearVision CK (Conductive Keratoplasty).
Frinzi, who began his career at Johnson & Johnson, is a 25+ year veteran of the ophthalmic and medical device industries. Before joining Refractec in 2000, he served as vice president of sales at Bausch & Lomb, managing numerous product launches focused on growth and expansion of the ophthalmic market. His ophthalmic career also includes long tenures at Chiron Vision Corp. and Iolab Corp.
“The board appreciates Mitch’s nine years of service and the large role he played in the company’s achievements. He had the foresight to see the promise of this technology and the industry is better for it,” said William Link, who assumes the chair of Refractec’s board following Campbell’s departure. “Given Tom’s exemplary qualifications and broad experience in the ophthalmic field, it comes as no surprise that he has the board’s unanimous support to take Refractec to the next level. His recent tenure as COO makes him uniquely qualified to shape the company’s future.”
“The 150,000 NearVision CK treatments performed to date demonstrates the maturation of our technology in the marketplace. Going forward, the exciting opportunity for us will be to continue to serve an emerging presbyopic market,” said Frinzi. “With baby boomers dominating the demographics, CK is uniquely positioned for growth in treating emmetropic presbyopia in virgin, post-IOL and post-LASIK eyes.”
About Refractec
Refractec, Inc. is a privately held ophthalmic technology company that develops and markets minimally invasive procedures for ophthalmologists and their baby boomer patients. Based in Irvine, Calif., Refractec provides “Corrective Solutions for Near Vision” with its proprietary NearVision CK (Conductive Keratoplasty) technology. Patients can visit (www.myclearvision.com) or call 1-800-752-9544 for more information on NearVision CK and to obtain a list of physicians.
www.myclearvision.com
Source: Refractec, Inc.
